Abstract 554P
Background
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a useful diagnostic modality for thoracic lymphadenopathies, including primary lung cancer. However, the specimens obtained are often small and inadequate for pathological diagnosis. We previously reported that using the EchoTip ProCore Endobronchial HD ultrasound needle (EchoTip) increased the tissue diagnosis rate in lung cancer (Miyazaki et al., 2021). In previous studies, the Oncomine Dx Target Test (ODxTT) was performed in only one case, and it is unclear whether the specimens collected could tolerate next-generation sequencing (NGS)-based testing.
Methods
We performed a single-center, retrospective observational study. This study included patients who underwent ODxTT between April 1, 2019 and April 30, 2023. Patients were selected and divided into two groups comprising those who underwent EBUS-TBNA and those whose specimens were obtained by other methods. The ODxTT success rate was calculated for each group. This study was approved by the institutional review board in June 2022. (No. 22-06-05).
Results
We enrolled 144 patients:20 in the EBUS-TBNA group and 124 in the other-methods group. In the EBUS-TBNA group, the pathological diagnoses were adenocarcinoma (Ad), squamous cell carcinoma (Sq), and others in 15, 2, and 3 patients, respectively. In contrast, in the other-methods group, the collection methods were endobronchial biopsy and transbronchial biopsy, surgical procedures, computed tomography-guided needle biopsy, and others for 79, 31, 6, and 8 patients, respectively, and the pathological diagnoses were Ad, Sq, and others in 78, 15, and 31 patients, respectively. The success rates of ODxTT for EBUS-TBNA and others were 90% and 86%, respectively. The DNA and RNA inspection success rates of EBUS-TBNA were 95% and 90%, respectively, and those of the other methods were 90% and 94%, respectively.
Conclusions
The success rate of ODxTT on EBUS-TBNA specimens were 90%. It is expected to yield specimens of sufficient quality and quantity to perform ODxTT and may be an important diagnostic option in lung cancer cases with enlarged lymph nodes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Miyazaki: Financial Interests, Personal, Invited Speaker: AstraZeneca, Merck KGaA, Eli Lilly Japan K.K., Cook Medical Japan; Financial Interests, Institutional, Research Grant: AbbVie GK, MSD, AstraZeneca, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD. K. Ito, A. Hayashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. A. Shiba: Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Taiho Pharmaceutical CO., LTD., Bristol Myers Squibb, AbbVie GK. Y. Higashi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK. M. Aga: Financial Interests, Personal, Invited Speaker: TEIJIN PHARMA, Nippon Boehringer Ingelheim Co., Ltd.; Financial Interests, Institutional, Research Grant: AbbVie GK, Bristol Myers Squibb, Taiho Pharmaceutical CO., LTD., MSD, AstraZeneca. Y. Hamakawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., AstraZeneca, AbbVie GK. Y. Taniguchi: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD. Y. Misumi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Nippon Kayaku CO., LTD., Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: MSD, AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD. Y. Agemi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Ono Pharmaceutical CO., LTD., Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Kyowa Hakko Kirin Co., Ltd.; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, AbbVie GK, Taiho Pharmaceutical CO., LTD., MSD. Y. Nakamura: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical CO., LTD, Taiho Pharmaceutical CO., LTD.; Financial Interests, Institutional, Research Grant: AstraZeneca, Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AbbVie GK. T. Shimokawa: Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical CO., LTD., MSD, Bristol Myers Squibb, AstraZeneca, AbbVie GK. H. Okamoto: Financial Interests, Institutional, Research Grant: MSD, Taiho, Bristol Myers Squibb.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract